REMSleep Holdings Inc., a medical device company focused on innovative sleep apnea treatment solutions, has announced the passing of its founder Thomas Wood and the appointment of Jeffrey Marshall as Chief Executive Officer. Wood, who founded REMSleep and served as Chairman and CEO, passed away on February 26, 2026, after dedicating his career to developing better solutions for sleep apnea patients.
Wood's design journey began in 1981 when he secured his first U.S. patent for the Nasal Air interface, eventually being awarded 26 patents for various components of CPAP interfaces. His relentless pursuit of better sleep apnea treatment led to the formation of REMSleep Holdings Inc. and the development of the DeltaWave Nasal Pillow System. "Tom was more than a founder, he was a visionary and patient advocate who believed that sleep apnea patients deserved better options," said Anita Michaels, who has been elected Chairman of the Board.
Under Wood's leadership, REMSleep achieved significant regulatory and commercial milestones including FDA 510(k) clearance for the DeltaWave Nasal Pillow System, PDAC coding approval enabling Medicare reimbursement, and buildout of manufacturing and distribution infrastructure. The company is now positioned for commercial launch and market entry with its flagship product, which is the first in what management envisions as a broader portfolio of solutions built on Wood's patented technologies.
The leadership transition was planned prior to Wood's passing, with the founder working alongside his sister Anita Michaels, who served as COO, and incoming CEO Jeff Marshall to establish the necessary systems and strategy. The Board of Directors has been reconstituted to ensure continuity and strong governance, with Anita Michaels elected as Chairman, Jeffrey Marshall appointed as CEO and Director, and Alexander Johnson appointed as Director.
Marshall brings extensive industry experience in sales, marketing, business development, and commercial strategy to lead REMSleep's next phase of growth. He has served as a strategy consultant to REMSleep since September 2025 and contributed to the company's strategic plan. "This transition is a pivotal moment for REMSleep," said Marshall. "Tom built the foundation achieving FDA clearance, Medicare approval, and a differentiated product. Now it's our job to execute the commercial opportunity he created."
The company's immediate priorities include driving sales through strategic sales and marketing plans to gain brand awareness and bring DeltaWave to patients nationwide. REMSleep aims to build partnerships with Durable Medical Equipment providers, physicians, sleep labs, and the entire sleep community. The DeltaWave technology represents more than just a sleep apnea solution—Wood's original vision extended to applying the same engineering principles to help patients battling other chronic respiratory and neurological diseases, which is now part of the company's strategic roadmap.
For more information about the company and its products, visit https://www.remsleep.com. "Tom's passing is a profound loss, but his work is far from finished," said Anita Michaels. "We have a responsibility to our shareholders, to sleep apnea patients, and to Tom's memory to see this through. With Jeff's leadership and our reconstituted Board, REMSleep is well-positioned to deliver on the promise of the DeltaWave technology and develop the pipeline of products Tom envisioned."
